Eradication of CD44-variant positive population in head and neck tumors through controlled intracellular navigation of cisplatin-loaded nanomedicines

Journal of Controlled Release

Volumn 230, Issue , 2016, Pages 26-33

  Wang, Ming ^a   Miura, Yutaka ^b   Tsuchihashi, Kenji ^c,d   Miyano, Kazuki ^b   Nagano, Osamu ^c   Yoshikawa, Momoko ^c   Tanabe, Ami ^b   Makino, Jun ^b   Mochida, Yuki ^e   Nishiyama, Nobuhiro ^e,f   Saya, Hideyuki ^c   Cabral, Horacio ^a   Kataoka, Kazunori ^a,b,e  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e Kawasaki Institute of Industry Promotion   (Japan)

^f TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Cancer therapy; CD44 variant; Drug delivery; Head and neck tumor; Polymeric micelle

Indexed keywords

CELL CULTURE; CELL PROLIFERATION; CHEMOTHERAPY; CYTOLOGY; DETOXIFICATION; DISEASES; DRUG DELIVERY; MEDICAL NANOTECHNOLOGY; MICELLES; PATIENT TREATMENT; PLATINUM; PLATINUM COMPOUNDS; POLYMERS; STEM CELLS; TUMORS;

CANCER THERAPY; CD44-VARIANT; DETOXIFICATION MECHANISM; HEAD-AND-NECK TUMOR; IMMUNOHISTOCHEMISTRY; PLATINUM-BASED CHEMOTHERAPY; POLYMERIC MICELLE; UNDIFFERENTIATED CELLS;

POPULATION STATISTICS;

ALDEHYDE DEHYDROGENASE; CD44V ANTIGEN; CISPLATIN; GLUTATHIONE; POLYMER; ANTINEOPLASTIC AGENT; CD44 PROTEIN, HUMAN; DNA; DRUG CARRIER; HYALURONIC ACID BINDING PROTEIN; PLATINUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CELL HYPOXIA; CELL POPULATION; CONTROLLED STUDY; DNA CROSS LINKING; DRUG DETOXIFICATION; DRUG EFFICACY; FEMALE; HEAD AND NECK TUMOR; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MICELLE; MOUSE; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; TUMOR CELL LINE;

ALDEHYDE DEHYDROGENASE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DNA; DRUG CARRIERS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; HYALURONAN RECEPTORS; MICE, INBRED BALB C; MICELLES; NANOMEDICINE; PLATINUM;

EID: 84962636017     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.03.038     Document Type: Article

References (59)

1. S. Marur, and A.A. Forastiere Head and neck cancer: changing epidemiology, diagnosis, and treatment Mayo Clin. Proc. 83 2008 489 501
2. A.A. Forastiere, H. Goepfert, M. Maor, T.F. Pajak, R. Weber, W. Morrison, and et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer N. Engl. J. Med. 349 2003 2091 2098
3. The globocan project World health organization home page http://globocan.iarc.fr/Pages/fact-sheets-population.aspx 2012 (accessed September 12, 2014)
4. M.E. Prince, R. Sivanandan, A. Kaczorowski, G.T. Wolf, M.J. Kaplan, P. Dalerba, and et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma Proc. Natl. Acad. Sci. U. S. A. 104 2007 973 978
5. M.E. Prince, and L.E. Ailles Cancer stem cells in head and neck squamous cell cancer J. Clin. Oncol. 26 2008 2871 2875
6. M. Dean, T. Fojo, and S. Bates Tumour stem cells and drug resistance Nat. Rev. Cancer 5 2005 275 284
7. M. Grimm, M. Krimmel, J. Polligkeit, D. Alexander, A. Munz, S. Kluba, and et al. ABCB5 expression and cancer stem cell hypothesis in oral squamous cell carcinoma Eur. J. Cancer 48 2012 3186 3197
8. C.T. Jordan, M.L. Guzman, and M. Noble Mechanisms of disease - cancer stem cells N. Engl. J. Med. 355 2006 1253 1261
9. H. Lage An overview of cancer multidrug resistance: a still unsolved problem Cell. Mol. Life Sci. 65 2008 3145 3167
10. T. Ishimoto, O. Nagano, T. Yae, M. Tamada, T. Motohara, H. Oshima, and et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth Cancer Cell 19 2011 387 400
11. T. Yae, K. Tsuchihashi, T. Ishimoto, T. Motohara, M. Yoshikawa, G.J. Yoshida, and et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell Nat. Commun. 3 2012 883
12. M. Yoshikawa, K. Tsuchihashi, T. Ishimoto, T. Yae, T. Motohara, E. Sugihara, and et al. xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma Cancer Res. 73 2013 1855 1866
13. S. Fierro, M. Yoshikawa, O. Nagano, K. Yoshimi, H. Saya, and Y. Einaga In vivo assessment of cancerous tumors using boron doped diamond microelectrode Sci. Rep. 2 2012 901
14. Q. Xu, N.V. Kolev, Q.G. Wright, I.M. Shapiro, C.M. Vidal, M. Padval, and et al. Focal adhesion kinase (FAK) inhibitors VS-6063 and VS-4718 target cancer stem cells J. Clin. Oncol. 31 2013 e13523
15. P.B. Gupta, T.T. Onder, G. Jiang, K. Tao, C. Kuperwasser, R.A. Weinberg, and et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening Cell 138 2009 645 659
16. Y. Zhang, H. Zhang, X. Wang, J. Wang, X. Zhang, and Q. Zhang The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles Biomaterials 33 2012 679 691
17. E. Sachlos, R.M. Risueño, S. Laronde, Z. Shapovalova, J.H. Lee, J. Russell, and et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells Cell 149 2012 1284 1297
18. H.A. Hirsch, D. Iliopoulos, and K. Struhl Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth Proc. Natl. Acad. Sci. U. S. A. 110 2013 972 977
19. K. Kataoka, A. Harada, and Y. Nagasaki Block copolymer micelles for drug delivery: design, characterization and biological significance Adv. Drug Deliv. Rev. 47 2001 113 131
20. H. Cabral, N. Nishiyama, and K. Kataoka Supramolecular nanodevices: from design validation to theranostic nanomedicine Acc. Chem. Res. 44 2011 999 1008
21. N. Nishiyama, and K. Kataoka Preparation and characterization of size-controlled polymeric micelle containing cis-dichlorodiammineplatinum(II) in the core J. Control. Release 74 2001 83 94
22. N. Nishiyama, Y. Kato, Y. Sugiyama, and K. Kataoka Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system Pharm. Res. 18 2001 1035 1041
23. N. Nishiyama, S. Okazaki, H. Cabral, M. Miyamoto, Y. Kato, Y. Sugiyama, and et al. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice Cancer Res. 63 2003 8977 8983
24. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Control. Release 65 2000 271 284
25. A.K. Iyer, G. Khaled, J. Fang, and H. Maeda Exploiting the enhanced permeability and retention effect for tumor targeting Drug Discov. Today 11 2006 812 818
26. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392
27. H. Uchino, Y. Matsumura, T. Negishi, F. Koizumi, T. Hayashi, T. Honda, and et al. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats Br. J. Cancer 93 2005 678 687
28. R. Plummer, R.H. Wilson, H. Calvert, A.V. Boddy, M. Griffin, J. Sludden, and et al. A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours Br. J. Cancer 104 2011 593 598
29. N. Nishiyama, F. Koizumi, S. Okazaki, Y. Matsumura, K. Nishio, and K. Kataoka Differential gene expression profile between PC-14 cells treated with free cisplatin and cisplatin-incorporated polymeric micelles Bioconjug. Chem. 14 2003 449 457
30. M. Murakami, H. Cabral, Y. Matsumoto, S. Wu, M.R. Kano, T. Yamori, and et al. Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting Sci. Transl. Med. 3 2011 64ra2
31. H. Cabral, and K. Kataoka Progress of drug-loaded polymeric micelles into clinical studies J. Control. Release 190 2014 465 476
32. B.B. Zhou, H. Zhang, M. Damelin, K.G. Geles, J.C. Grindley, and P.B. Dirks Tumour-initiating cells: challenges and opportunities for anticancer drug discovery Nat. Rev. Drug Discov. 8 2009 806 823
33. S.P. McDermott, and M.S. Wicha Targeting breast cancer stem cells Mol. Oncol. 4 2010 404 419
34. M.V. Blagoskylonny Target for cancer therapy: proliferating cells or stem cells Leukemia 20 2006 385 391
35. I. Baccelli, and A. Trumpp The evolving concept of cancer and metastasis stem cells J. Cell Biol. 198 2012 281 293
36. S. Urien, and F. Lokiec Population pharmacokinetics of total and unbound plasma cisplatin in adult patients Br. J. Clin. Pharmacol. 57 2004 756 763
37. C. Ginestier, M.H. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, M. Brown, and et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome Cell Stem Cell 1 2007 555 567
38. P. Marcato, C.A. Dean, C.A. Giacomantonio, and P.W. Lee Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform Cell Cycle 10 2011 1378 1384
39. J.T. Connelly, J.E. Gautrot, B. Trappmann, D.W. Tan, G. Donati, W.T. Huck, and et al. Actin and serum response factor transduce physical cues from the microenvironment to regulate epidermal stem cell fate decisions Nat. Cell Biol. 12 2010 711 718
40. A. Meister Glutathione metabolism and its selective modification J. Biol. Chem. 263 1988 17205 17208
41. M.H. Hanigan, and W.A. Ricketts Extracellular glutathione is a source of cysteine for cells that express γ-glutamyl transpeptidase Biochemistry 32 1993 6302 6306
42. A. Brüning, K. Friese, A. Burges, and L. Mylonas Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells Breast Cancer Res. 12 2010 R45
43. M.H. Hanigan, B.C. Gallagher, D.M. Townsend, and V. Gabarra γ-Glutamyl transpeptidase accelerates tumor growth and increase the resistance of tumors to cisplatin in vivo Carcinogenesis 20 1999 553 559
44. A. Pompella, V. De Tata, A. Paolicchi, and F. Zunino Expression of γ-glutamyltransferase in cancer cells and its significance in drug resistance Biochem. Pharmacol. 71 2006 231 238
45. V.I. Lushchak Glutathione homeostasis and functions: potential targets for medical interventions J. Amino Acids 2012 2012 736837
46. N. Dizdar, A. Kullman, B. Kågedal, and K. Årstrand Effects on interstitial glutathione, cysteine and 5-S-cysteinyldopa by buthionine sulfoximine in human melanoma transplants Melanoma Res. 7 1997 322 328
47. N. Dizdar, A. Kullman, and B. Kågedal Comparison of N-acetylcysteine and L-2-oxothiazolidine-4-carboxylate as cysteine deliverers and glutathione precursors in human malignant melanoma transplants in mice Cancer Chemother. Pharmacol. 45 2000 192 198
48. Z.H. Siddik Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 22 2003 7265 7279
49. N. Shafee, C.R. Smith, S. Wei, Y. Kim, G.B. Mills, G.N. Hortobagyi, and et al. Cancer stem cells contribute to cisplatin resistance in brca1/p53-mediated mouse mammary tumors Cancer Res. 68 2008 3243 3250
50. F. Notta, C.G. Mullighan, J.C. Wang, A. Poeppl, S. Doulatov, L.A. Phillips, and et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells Nature 469 2011 362 367
51. C.G. Mullighan, L.A. Phillips, X. Su, J. Ma, C.B. Miller, S.A. Shurtleff, and et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia Science 322 2008 1377 1380
52. G. Bertolini, L. Roz, P. Perego, M. Tortoreto, E. Fontanella, L. Gatti, and et al. Highly tumorigenic lung cancer CD133 + cells display stem-like features and are spared by cisplatin treatment Proc. Natl. Acad. Sci. U. S. A. 106 2009 16281 16286
53. H. Cabral, Y. Matsumoto, K. Mizuno, Q. Chen, M. Murakami, M. Kimura, and et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size Nat. Nanotechnol. 6 2011 815 823
54. S. Marrache, R.K. Pathak, and S. Dhar Detouring of cisplatin to access mitochondrial genome for overcoming resistance Proc. Natl. Acad. Sci. U. S. A. 111 2014 10444 10449
55. S. Goto, K. Yoshida, T. Morikawa, Y. Urata, K. Suzuki, and T. Kondo Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer-cells Cancer Res. 55 1995 4297 4301
56. Y. Kasherman, S. Sturup, and D. Gibson Is glutathione the major cellular target of cisplatin? A study of the interactions of cisplatin with cancer cell extracts J. Med. Chem. 52 2009 4319 4328
57. Z. Yang, P.J. Faustino, P.A. Andrews, R. Monastra, A.A. Rasmussen, C.D. Ellison, and et al. Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines Cancer Chemother. Pharmacol. 46 2000 255 262
58. A.M. Fichtinger-Schepman, J.L. van der Veer, J.H. den Hartog, P.H. Lohman, and J. Reedijk Adducts of the antitumor drug cis-diamminedichloroplatinum(ii) with DNA: formation, identification, and quantitation Biochemistry 24 1985 707 713
59. R.J. Parker, A. Eastman, F. Bostick-bruton, and E. Reed Acquired cisplatin resistance in human ovarian-cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation J. Clin. Investig. 87 1991 772 777